Investigational · Not FDA-approved · Not offered by REMEVi
Retatrutide (three receptors), tirzepatide (two) and semaglutide (one) were studied separately: 28.3% weight loss at 80 weeks (TRIUMPH-1), −20.9% at 72 weeks (SURMOUNT-1), −14.9% at 68 weeks (STEP 1). Investigational: not FDA-approved, not prescribable in the US, and REMEVi does not offer it.
Trial results, not REMEVi averages; individual results vary.
For compounded semaglutide or tirzepatide — not retatrutide. No card to start.
Ver en Español§ 01 · Side by side
01 / 06This is not a ranking. Every column is a different molecule studied in a different trial, and every figure links the study that produced it.
Swipe the table sideways to see all three columns →
| Fact | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptors | Three — GIP, GLP-1 and glucagon | Two — GIP and GLP-1 | One — GLP-1 |
| Trial | TRIUMPH-1 | SURMOUNT-1 | STEP 1 |
| Duration | 80 weeks | 72 weeks | 68 weeks |
| Average weight change | −28.3% | −20.9% | −14.9% |
| Status | Investigational — not FDA-approved, not prescribable, and it cannot be compounded under federal law | FDA-approved as a brand product; a compounded preparation is available by prescription | FDA-approved as a brand product; a compounded preparation is available by prescription |
These are separate trials with different designs, populations and durations — not head-to-head comparisons. Trial results, not REMEVi averages; individual results vary.
In SURMOUNT-1 (NEJM, 2022), tirzepatide 15 mg weekly produced a mean body-weight reduction of −20.9% at 72 weeks, on the treatment-regimen estimand.
In STEP 1 (NEJM, 2021), semaglutide 2.4 mg weekly produced a mean body-weight change of −14.9% at 68 weeks, against −2.4% on placebo.
Semaglutide is the medication in Ozempic® and Wegovy®; tirzepatide is the medication in Mounjaro® and Zepbound®. Those are FDA-approved products of Novo Nordisk and Eli Lilly; REMEVi is not affiliated with either company. A compounded preparation from a state-licensed US 503A pharmacy is not FDA-approved and is not a generic version of any of them.
§ 02 · Difference
02 / 06In two ways that matter and a third that matters more. First, the receptors: tirzepatide acts on two (GIP and GLP-1) and retatrutide on three (GIP, GLP-1 and glucagon). Second, the stage: tirzepatide finished its phase 3 programme years ago and has FDA-approved brand products; retatrutide is still in phase 3.
And the third: tirzepatide can be prescribed today. Retatrutide cannot. A licensed provider can evaluate you and prescribe compounded tirzepatide; nobody in the United States can prescribe you retatrutide outside a clinical trial, and federal law does not allow a pharmacy to compound it.
Eli Lilly Medical — mechanism of action, accessed September 9, 2026
§ 03 · Comparison
03 / 06The published trials cannot answer that. TRIUMPH-1 and SURMOUNT-1 are separate studies with different populations, designs, durations and eras, and neither one included the other drug as a comparator. Setting their percentages side by side shows what each trial reported; it does not show what would happen if the two were run against each other.
The first trial designed to compare them directly is TRIUMPH-5, registered with an obesity population and tirzepatide as the comparator. As of September 2026 it has not reported results, and we will not publish an answer before one exists.
Trial results, not REMEVi averages; individual results vary.
§ 04 · Brands
04 / 06That question compares a molecule with a brand, so the names are worth sorting first. Semaglutide is the medication in Ozempic® and Wegovy®; tirzepatide is the medication in Mounjaro® and Zepbound®. Retatrutide has no brand because it has no approval: there is no branded retatrutide product in any country.
So the practical difference is the same one this whole page keeps arriving at: one of these molecules can be prescribed in the United States today and the other cannot.
Semaglutide is the medication in Ozempic® and Wegovy®; tirzepatide is the medication in Mounjaro® and Zepbound®. Those are FDA-approved products of Novo Nordisk and Eli Lilly; REMEVi is not affiliated with either company. A compounded preparation from a state-licensed US 503A pharmacy is not FDA-approved and is not a generic version of any of them.
§ 05 · Side effects
05 / 06Each block reports what THAT trial’s own publication or release said. They are not compared with each other and they are not added together: different populations, different designs.
At the highest dose studied in TRIUMPH-1, nausea was reported by 42.4% of participants against 14.8% on placebo, and diarrhea by 32.0% against 13.5% on placebo.
In TRIUMPH-4, 18.2% of participants at the highest dose studied stopped treatment because of adverse events, against 4.0% on placebo. The most common adverse events reported at that dose were nausea (43.2%), diarrhea (33.1%), constipation (25.0%) and vomiting (20.9%).
Trial results, not REMEVi averages; individual results vary.
Eli Lilly press release — TRIUMPH-1 results, May 21, 2026
Eli Lilly press release — TRIUMPH-4 results, December 11, 2025
The source pack behind this page does not carry gastrointestinal rates from SURMOUNT-1, so we publish none: the reported rates are in the NEJM paper itself, linked below. What this page does stand behind is the weight figure and its estimand. The side effects of compounded tirzepatide that we do describe, and the honest part about the first weeks, are on its product page.
Trial results, not REMEVi averages; individual results vary.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM, July 21, 2022
Same here: the source pack carries no gastrointestinal rates from STEP 1 and we do not invent any. The NEJM paper is linked below, and the side effects of compounded semaglutide are on its product page.
Trial results, not REMEVi averages; individual results vary.
§ What you can get
06 / 06Two of the three. Semaglutide and tirzepatide are FDA-approved as brand products and are available as a compounded preparation on a licensed provider’s prescription. Retatrutide is not available by any lawful route outside a trial.
Semaglutide from $159/mo on the 24-week plan — $169/mo on the 12-week plan, $199/mo month-to-month. The same price at every dose, all-inclusive.
In STEP 1 (NEJM, 2021), semaglutide 2.4 mg weekly produced a mean body-weight change of −14.9% at 68 weeks, against −2.4% on placebo.
Trial results, not REMEVi averages; individual results vary.
Everything about compounded semaglutideTirzepatide from $225/mo on the 24-week plan — $233/mo on the 12-week plan, $269/mo month-to-month. The same price at every dose, all-inclusive.
In SURMOUNT-1 (NEJM, 2022), tirzepatide 15 mg weekly produced a mean body-weight reduction of −20.9% at 72 weeks, on the treatment-regimen estimand.
Trial results, not REMEVi averages; individual results vary.
Everything about compounded tirzepatideThat price includes
a licensed provider visit · the medication · cold-chain shipping · monthly follow-up · the portal and a care coordinator in English or Spanish
No membership fee · cancel any time · refund if a provider doesn't approve you.
And to check us
Semaglutide is the medication in Ozempic® and Wegovy®; tirzepatide is the medication in Mounjaro® and Zepbound®. Those are FDA-approved products of Novo Nordisk and Eli Lilly; REMEVi is not affiliated with either company. A compounded preparation from a state-licensed US 503A pharmacy is not FDA-approved and is not a generic version of any of them.
§ FAQ
04 entriesNobody honest can say yet. Retatrutide is not approved, no application for approval has been submitted, and there is no product anyone can prescribe. What replaces what will depend on regulatory and clinical decisions that have not happened.
There is nothing to switch to today: retatrutide is not available by prescription in the United States. If it is ever approved and available through our partner pharmacies, we will say so here. And either way, which medication is appropriate for you is decided by the licensed provider who reviews your history, not by a web page.
Two of the three. Our licensed providers prescribe compounded semaglutide and compounded tirzepatide, prepared by state-licensed US 503A pharmacies under an individual prescription. We do not offer retatrutide.
No. TRIUMPH-1, SURMOUNT-1 y STEP 1 son ensayos independientes, con poblaciones, diseños y duraciones distintas, y ninguno usó a los otros medicamentos como comparador. Por eso esta página los presenta como puntos de referencia separados y no como una competencia. El primer ensayo diseñado para comparar retatrutida y tirzepatida de frente es TRIUMPH-5 y todavía no ha reportado resultados.
§ Sources
Primary sources only: peer-reviewed journals, the FDA, and Eli Lilly’s own medical and investor sites. If a figure is not in this list, it is not on the page.
Retatrutide is not one of them. What our licensed providers do prescribe is compounded semaglutide and compounded tirzepatide, with the price published before you give us anything. The secure intake takes about 2 minutes, no card to start, in English or Spanish.
